Key Metrics

Market Cap	45.87M
Total Shares Outstanding	2.61M
Book Value	-11.84
PE Ratio	-

PS Ratio	38.03
PB Ratio	2.53
Forward PE Ratio	-
ROIC	-

Return on Aseets	-41.48
Return on Equity	-362.13
Dividend	-
Dividend Yield	-

Balancesheet Metrics

Total Assets	43.16M
Total Liability	25.25M
Assets-to-Libability Ratio	1.71

Total Current Assets	42.96M
Total Current Liability	6.42M
Current Ratio	6.69

Quick Ratio	-
Debt to Equity Ratio	-

Income Statement Metrics

Net Income	-12.99K
EPS	-4.37
EBITA	-12.86K

Gross Profit	4.00K
Gross Profit Margin	-
Operating Margin	-2.29K%

Net Profit Margin

-324.27%

Price Metrics

5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA

52 Weeks High
52 Weeks low
All Time High

RSI
MACD

Share Stats

Shares Float	883.71K
Shares Short	27.93K

% Short	0.0333%
% Insider	38.818%

% Institutions	14.949%

% Institutions

14.949%

News

Profile

vTv Therapeutics Inc (VTVT)

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.

Exchange: NASDAQ

IPO Date: 7/30/2015

Sector: Healthcare

Industry: Biotechnology

Employees: 16

Address: 3980 Premier Drive, High Point, NC, United States, 27265

https://vtvtherapeutics.com

Quarterly Yearly

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	Totals
	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	Totals
Assets	43.16K	46.46K	54.18K	11.02K	14.92K	22.43K	28.83K	33.24K	35.52K	36.99K	1.19M
Current Assets	42.96K	46.20K	53.87K	10.66K	10.13K	13.94K	20.63K	27.09K	28.78K	30.61K	977.94K
Cash And Short Term Investments	41.57K	45.53K	52.26K	9.45K	8.24K	12.60K	18.77K	12.13K	15.34K	17.86K	880.00K
Net Receivables	242	306	981	102	-	-	-	12.42K	12.15K	12.02K	52.63K
Inventory	-	-65	0.001	-	-	-	-	15	-	-	-49.998999999999995
Other Current Assets	1.15K	433	636	1.11K	1.87K	1.32K	1.85K	2.54K	1.28K	643	36.75K
Non Current Assets	206	258	310.999	361	4.80K	8.49K	8.20K	6.14K	6.73K	6.38K	210.99K
Property Plant Equipment	-	-	-	-	-	162	185	207	230	254	24.43K
Long Term Investments	-	-	-	-	4.39K	8.03K	7.69K	5.59K	6.17K	5.77K	121.58K
Non Currrent Assets Other	-	-0.001	-0.001	-	-	299	-8.20K	-6.14K	328	354	56.31K
Liabilities	25.25K	26.02K	28.20K	29.57K	29.43K	28.83K	48.02K	43.98K	52.09K	45.52K	3.76M
Current Liabilities	6.42K	6.99K	8.92K	10.62K	10.28K	9.29K	8.53K	7.71K	7.47K	9.82K	558.09K
Accounts Payable	-	6.79K	8.73K	4.08K	-17	-17	8.36K	2.46K	6.68K	9.60K	287.30K
Short Long Term Debt	-	-	-	191	473	-	-	224	557	-	115.54K
Other Current Liabilities	6.24K	-177	8.75K	7.29K	9.64K	9.13K	8.36K	4.85K	6.68K	26	151.23K
Non Current Liabilities	18.83K	19.04K	19.27K	18.95K	19.16K	19.54K	39.49K	36.27K	44.62K	35.69K	3.20M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	127.34K
Other Liabilities	-	-	-	-	-	19.29K	-	19.35K	20.08K	19.39K	226.93K
Stockholder Equity	15.01K	16.48K	20.80K	-24.68K	-25.23K	-25.28K	-19.19K	-10.74K	-16.57K	-8.53K	-2.56M
Preferred Stock Equity	-	-	-	-	-	-	-	-	-	-	1.44M
Liabilities And Stockholders Equity	43.16K	46.46K	54.18K	11.02K	14.92K	22.43K	28.83K	33.24K	35.52K	36.99K	1.09M
Common Equity	-	-	-	-	-	1.05K	1.05K	1.05K	1.05K	1.00K	1.02M
Retained Earnings	-	-	-	-	-	-280.81K	-274.32K	-265.52K	-267.06K	-253.30K	-7.05M
Totals		244.20K	260.70K	311.09K	89.73K	103.00K	-129.30K	-72.94K	-33.91K	-2.38K	7.09K	154.89K	105.30K	-35.67K	-80.70K	-102.61K	-383.80K	-141.29K	-118.99K	-130.37K	-116.74K	-103.22K	-91.10K	-75.15K	157.89K	-42.31K	-23.25K	3.26K	87.91K	47.57K	137.72K	195.56K	237.30K	216.82K	289.18K	367.32K	440.04K	490.73K	1.34M	1.25M	1.06M	-	-	-	5.92M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014	Totals
	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014	Totals
Assets	11.02K	33.24K	25.47K	14.79K	9.27K	8.56K	27.92K	54.49K	91.53K	12.95K	289.24K
Current Assets	10.66K	27.09K	15.62K	7.21K	2.84K	3.47K	20.36K	52.12K	89.19K	1.61K	230.17K
Cash And Short Term Investments	9.45K	12.13K	13.41K	5.75K	1.78K	1.68K	11.76K	51.51K	88.00K	-	195.46K
Net Receivables	102	12.42K	57	158	5	-	8.00K	-	69	-	20.81K
Inventory	-	15	100	371	-	-	-	-	-	-	486
Other Current Assets	1.11K	2.54K	2.15K	939	806	1.79K	604	612	1.11K	97	11.76K
Non Current Assets	361	6.14K	9.85K	7.57K	6.43K	5.09K	7.55K	2.38K	2.35K	11.34K	59.06K
Property Plant Equipment	-	207	680	367	1.00K	70	283	444	624	3.78K	7.46K
Long Term Investments	-	5.59K	9.17K	6.72K	2.48K	2.48K	2.48K	-	-	7.45K	36.38K
Non Currrent Assets Other	-	-6.14K	-	-7.57K	2.94K	2.54K	4.79K	1.93K	1.72K	7.56K	7.77K
Liabilities	29.57K	43.98K	35.21K	94.89K	58.29K	91.41K	178.96K	145.44K	169.50K	511.76K	1.36M
Current Liabilities	10.62K	7.71K	8.50K	6.39K	13.38K	18.84K	26.93K	11.43K	7.73K	6.86K	118.39K
Accounts Payable	4.08K	2.46K	1.88K	1.93K	7.07K	2.90K	2.27K	3.06K	4.14K	2.66K	32.44K
Short Long Term Debt	191	224	256	84	6.17K	9.38K	4.27K	11.06K	-	155	31.79K
Other Current Liabilities	6.17K	4.70K	5.96K	4.04K	4.84K	4.80K	11.63K	21	219	4.05K	46.43K
Non Current Liabilities	18.95K	36.27K	26.72K	88.50K	44.91K	72.58K	152.03K	134.01K	161.78K	504.89K	1.24M
Long Term Debt	-	-	-	-	-	6.33K	15.32K	11.06K	-	-	32.70K
Other Liabilities	-	19.35K	1.26K	3.93K	3.89K	3.76K	5.28K	433	245	30.79K	68.95K
Stockholder Equity	-24.68K	-10.74K	-9.74K	-80.10K	-49.02K	-82.85K	-151.05K	-90.94K	-77.97K	-498.81K	-1.08M
Preferred Stock Equity	-	-	-	-	-	-	232	232	237	438.09K	438.79K
Liabilities And Stockholders Equity	11.02K	33.24K	25.47K	14.79K	9.27K	8.56K	27.92K	54.49K	91.53K	12.95K	289.24K
Common Equity	-	1.05K	-	541	641	435	329	329	329	-	3.65K
Retained Earnings	-	-265.52K	-	-290.04K	-233.52K	-	-279.06K	-215.49K	-195.99K	-	-1.48M
Totals		88.60K	-34.07K	172.04K	-118.74K	-106.54K	161.82K	78.82K	228.62K	436.35K	1.06M	1.97M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	06/30/2022	03/31/2022	12/31/2021	09/30/2021	06/30/2021	03/31/2021	12/31/2020	09/30/2020	06/30/2020	03/31/2020	Totals
	06/30/2022	03/31/2022	12/31/2021	09/30/2021	06/30/2021	03/31/2021	12/31/2020	09/30/2020	06/30/2020	03/31/2020	Totals
Revenue	9	2.00K	4.005	3.00K	9	987	6.414	7	-	8	24.22K
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	212.06K
Gross Profit	9	-	4.005	3.00K	9	987	6.414	7	-	8	-80.58K
Operating Expenses	4.04K	8.48K	-14.52K	4.60K	4.68K	5.27K	-4.19K	2.84K	4.20K	6.65K	253.70K
Selling General Administrative	1.83K	5.35K	-6.61K	2.22K	2.24K	2.16K	2.04K	1.07K	1.70K	2.45K	74.24K
Research Development	2.21K	3.13K	-7.91K	2.38K	2.44K	3.10K	-2.50K	1.77K	2.51K	4.20K	183.19K
Other Operating Expenses	-	8.48K	-	4.60K	4.68K	5.27K	2.2228	2.84K	4.20K	6.65K	268.38K
Operating Income	-4.03K	-6.48K	-11.11K	-1.60K	-4.67K	-4.28K	4.1912	-2.83K	-4.20K	-6.65K	-259.30K
Net Interest Income	50	-1	-6	-6	-	1	-67	-235	-222	-156	-2.42K
Interest Income	50	-	-	-	-	1	-	-	-	12	-510
Interest Expense	-	1	-5.988	6	-	1	67	235	222	168	16.99K
Other Income Expense Net	-114	-2.74K	19.22K	238	3.83K	-1.65K	0.787	-579	787	519	37.95K
Income Before Tax	-4.09K	-9.22K	8.12K	-1.36K	-841	-5.93K	4.9782	-2.25K	-4.99K	-7.17K	-259.63K
Tax Provision	-	200	-	100	-	15	-	-	-	-	415
NetIncome	-3.15K	-7.01K	5.92K	-1.09K	-608	-4.24K	3.3552	-1.53K	-3.37K	-4.72K	-136.84K
NetIncome Applicable To Common Shares	-3.15K	-7.01K	-7.05K	-1.09K	-608	-4.24K	1.13K	-1.53K	-3.37K	-4.72K	-182.60K
Ebit	-4.14K	-6.81K	5.80K	-981	-608	-4.22K	70.3552	-2.83K	-4.20K	-6.65K	-218.54K
Basic EPS	-	-0.1	-0.11	-0.02	-0.01	-0.08	0.02	-0.03	-0.07	-0.11	-7.3
Totals		-10.49K	-11.63K	-8.15K	14.02K	10.55K	-6.77K	-3.42K	-3.03K	-6.74K	-9.38K	-9.37K	-7.65K	6.03K	-4.04K	20.43K	18.80K	22.54K	14.21K	-35.00K	5.13K	5.55K	6.00K	-51.66K	5.68K	6.73K	7.84K	-18.38K	2.25K	-1.13K	659	-31.39K	2.02K	834	-336	-69.28K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014	Totals
	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014	Totals
Revenue	4.005	6.41K	2.76K	12.43K	291	634	519	1.55K	24.61K
Cost Of Revenue	-	-	15.12K	23.04K	39.64K	45.75K	29.58K	29.58K	182.71K
Gross Profit	4.005	6.414	-12.36K	-10.60K	-39.35K	-45.11K	519	1.55K	-105.34K
Operating Expenses	25.667	18.27K	23.66K	32.26K	50.97K	55.65K	38.66K	30.45K	249.94K
Selling General Administrative	12.343	7.25K	8.54K	9.22K	11.33K	9.91K	9.08K	11.72K	67.06K
Research Development	13.324	11.02K	15.12K	23.04K	39.64K	45.75K	29.58K	18.73K	182.88K
Other Operating Expenses	-	18.27K	23.66K	32.26K	50.97K	55.65K	38.66K	30.45K	249.91K
Operating Income	-21.66K	-11.85K	-20.89K	-19.82K	-50.68K	-55.02K	-38.14K	-28.90K	-246.97K
Net Interest Income	-11	-680	-1.77K	-3.23K	-2.98K	-311	-	-	-8.98K
Interest Income	1	12	53	61	117	87	-1.74K	-	-1.40K
Interest Expense	0.012	692	1.83K	3.29K	3.09K	398	1.74K	6.01K	17.04K
Other Income Expense Net	21.64K	-950	-946	-3.82K	-3.17K	333	2.96K	7.20K	23.26K
Income Before Tax	-17.616	-12.80K	-21.84K	-23.64K	-53.85K	-55.35K	-41.11K	-36.10K	-244.71K
Tax Provision	115	-	100	200	800	-	-	-	1.22K
NetIncome	-12.987	-8.50K	-13.04K	-7.91K	-16.14K	-16.35K	-27.50K	-36.10K	-125.56K
NetIncome Applicable To Common Shares	-12.99K	-8.50K	-17.91K	-8.65K	-16.14K	-16.35K	-27.50K	-36.10K	-144.14K
Ebit	-12.86	-7.81K	-11.12K	-4.42K	-12.25K	-55.02K	-38.14K	-28.90K	-157.67K
Basic EPS	-0.22	-0.19	-0.62	-0.82	-1.67	-1.72	-1.96	-	-7.2
Totals		-12.88K	10.83K	-9.05K	53.69K	2.30K	-29.36K	-22.82K	-28.87K	-36.16K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	Totals
	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	Totals
Cash From Operating Activities	-6.42K	-6.73K	-7.33K	-2.91K	-4.83K	-6.17K	-5.17K	-6.88K	-8.83K	706	-283.97K
Net Income	-6.99K	-6.41K	-4.87K	-3.48K	-8.54K	-7.21K	-5.77K	-6.09K	-5.47K	-4.09K	-195.03K
Depreciation	22	23	22	23	22	23	22	23	24	22	2.43K
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-
Change Receivables	-	-	-	-	-	-	173	-	-	-	7.36K
Change To Inventory	-	-	-	-	-	-	-	-	-	-	-
Change To Liabilities	-	-	-	-	-	738	1.03K	-	-2.95K	3.88K	25.98K
Change To Net Income	-	-	-	-	-	64	-1.55K	-	-1.09K	-709	-79.44K
ChangeToOperatingActivities	-	-	-	-	-	-	522	-	-568	689	-4.45K
Cash flows From Investing Activities	-	-	-	-	-	-	-	-	-	-21	810
Capital Expenditures	-	-	-	-	-	-	-	-20.979	-21	-21	-1.06K
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	655
Cash From Financing Activities	2.46K	-	50.14K	-282	473	1.27K	11.81K	3.67K	6.30K	5.04K	463.56K
Net Borrowings	-	-	-	-	-	-	-224	-	557	557	57.86K
Sale Purchase Of Stock	-	-	-	-1.27K	-	1.27K	-	-	4.00K	-	257.13K
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-
Other Cashflows From Financing Activities	2.46K	-	50.34K	12.03K	566	-1.27K	11.81K	-1.04K	6.52K	-21	287.03K
Cash And Cash Equivalents Changes	-	-	-	-	-	-6.17K	6.64K	-	-	-	-62.34K
Totals		-8.46K	-13.12K	88.30K	4.10K	-12.31K	-17.45K	19.29K	-10.34K	-1.52K	6.03K	-5.27K	-9.57K	28.74K	7.79K	9.19K	20.15K	-11.78K	9.59K	3.93K	25.08K	21.39K	8.88K	13.54K	-1.64K	12.93K	-3.05K	-6.56K	-27.74K	-21.18K	-21.31K	-1.70K	-11.53K	-28.51K	-25.46K	-27.18K	120.59K	198.68K	6.12K	2.16K	139.55K	-1.25K	3.02K	-5.62K	476.53K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014	Totals
	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014	Totals
Cash From Operating Activities	-19.08K	-16.02K	-19.31K	-18.00K	-23.02K	-26.86K	-44.56K	-48.21K	-36.95K	-30.78K	-282.78K
Net Income	-20.25K	-25.07K	-17.73K	-12.80K	-21.94K	-7.91K	-16.14K	-16.35K	-27.50K	-36.10K	-201.80K
Depreciation	90	92	89	94	39	218	197	265	501	864	2.45K
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-
Change Receivables	-	-116	-	-153	-5	8.00K	-8.00K	118	-77	-	-233
Change To Inventory	-	-	-889	-1.98K	618	-	-	-	-	-	-2.25K
Change To Liabilities	-	-856	823	-1.21K	-618	-6.23K	13.20K	3.71K	5.61K	-180	14.25K
Change To Net Income	-	4.50K	-6.45K	1.01K	1.23K	2.66K	-34.68K	-36.36K	-11.99K	1.22K	-78.84K
ChangeToOperatingActivities	-	-403	-889	-1.53K	324	1.09K	-164	309	-3.50K	-771	-5.53K
Cash flows From Investing Activities	-	-21	-21	-21	242	7	-25	-83	-79	161	160
Capital Expenditures	-	-21	-21	-21	-70	-5	-57	-87	-104	-33	-419
Other Cashflows From Investing Activities	-	-	-	-	312	12	32	4	25	194	579
Cash From Financing Activities	12.00K	14.75K	26.98K	19.47K	22.87K	16.61K	7.50K	11.79K	123.64K	30.91K	286.53K
Net Borrowings	-	-32	172	-4.96K	-10.07K	-4.89K	7.50K	12.47K	19.20K	33.41K	52.80K
Sale Purchase Of Stock	-	9.75K	-	14.43K	992	21.50K	-	-	105.77K	-2.50K	149.94K
Dividends Paid	-	-	-	-	-992	-	-	-	-	-	-992
Other Cashflows From Financing Activities	4.40K	14.79K	26.80K	500	500	500	7.50K	11.79K	17.96K	33.56K	118.31K
Cash And Cash Equivalents Changes	-	-1.29K	-	1.47K	94	-10.24K	-37.09K	-36.50K	86.62K	-	3.07K
Totals		-22.84K	50	9.56K	-3.70K	-29.49K	-5.53K	-104.78K	-97.13K	279.14K	29.97K	55.24K

Profile

Free Stocks

Company

Features

Contact Us